TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10669686

Group type: EXPERIMENTAL
Intervention: Inhaled salbutamol (2 x 100 microg qid for 6 weeks)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo (identical to salbutamol, 2 x 100 microg qid for 6 weeks)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Inhaled salbutamol
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 9209926

Group type: EXPERIMENTAL
Intervention: Dialyzer with spacing filaments (PAN 650 SF Asahi)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard dialyzer without spacing filaments
Number of subjects: 0
Study: 8092771

Group type: EXPERIMENTAL
Intervention: Maxon
Number of subjects: 102

Group type: COMPARATOR
Intervention: Dexon Plus
Number of subjects: 102
Study: 3125004

Group type: EXPERIMENTAL
Intervention: Peptide enteral formula
Number of subjects: 12

Group type: COMPARATOR
Intervention: Standard isotonic enteral formula
Number of subjects: 12
Study: 30700257

Group type: EXPERIMENTAL
Intervention: Intervention group (N=5) received repeated safety climate (SC) measurement and feedback, and patient record reviews using a specialized trigger tool.
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control group (N=6) received baseline and end SC measurement only.
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Intervention group (N=5) applied the trigger tool to patient records.
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: End-of-study questionnaire for intervention group (N=5).
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Semi-structured interviews (N=9) with intervention group staff.
Number of subjects: 11
Study: 27986296

Group type: EXPERIMENTAL
Intervention: Mixed media education intervention (3 biweekly sessions with lectures, videos, role-play, and feedback)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Mixed media education intervention
Number of subjects: 84

Group type: COMPARATOR
Intervention: Self-directed readings (control group)
Number of subjects: 84
Study: 26317782

Group type: EXPERIMENTAL
Intervention: Hydrocortisone (HC) at doses of 6 mg/m2/d, 10 mg/m2/d, and 14 mg/m2/d administered thrice daily.
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Single point plasma cortisol measurements.
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Cortisol concentrations at 1000h and 1400h.
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: 0800-1200h ΔACTH measurements.
Number of subjects: 27
Study: 22672584

Group type: EXPERIMENTAL
Intervention: Immediately placed implants in sockets with periapical pathology
Number of subjects: 27

Group type: COMPARATOR
Intervention: Immediately placed implants in sockets without periapical pathology (control group)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Both groups (test and control)
Number of subjects: 27
Study: 21288341

Group type: EXPERIMENTAL
Intervention: Physical activity intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Depression awareness training
Number of subjects: 0
Study: 19692147

Group type: EXPERIMENTAL
Intervention: Ibuprofen 10 mg/kg
Number of subjects: 336

Group type: COMPARATOR
Intervention: Acetaminophen with codeine 1 mg/kg/dose
Number of subjects: 336
Study: 16984757

Group type: EXPERIMENTAL
Intervention: Artificial cycles with oral oestradiol and vaginal oestradiol if needed
Number of subjects: 163

Group type: COMPARATOR
Intervention: Stimulated cycles with recombinant FSH and human gonadotrophin hormone injection
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Artificial cycles switched to vaginal oestradiol
Number of subjects: 163
Study: 14626627

Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus GG (LGG)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 10790041

Group type: EXPERIMENTAL
Intervention: Amplitude increments of 2 dB or more
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Amplitude decrements of 3 dB or more
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Change of second formant frequency (from perceived /u/ to perceived /i/) with amplitude increments
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Change of second formant frequency (from perceived /u/ to perceived /i/) with amplitude decrements
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Spectral change with small amplitude change
Number of subjects: 8
Study: 9493920

Group type: EXPERIMENTAL
Intervention: Behavioral therapy (6 hours of training in sleep hygiene and relaxation)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Behavioral therapy with occasional hypnotics
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Behavioral therapy without hypnotics
Number of subjects: 26

Group type: COMPARATOR
Intervention: Waiting list (control group)
Number of subjects: 26
Study: 8348061

Group type: EXPERIMENTAL
Intervention: Isotretinoin (10 mg/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 2951803

Group type: EXPERIMENTAL
Intervention: Fenoterol (200 micrograms)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Duovent (fenoterol 200 micrograms plus ipratropium bromide 80 micrograms)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control (no drug)
Number of subjects: 17
Study: 30326954

Group type: EXPERIMENTAL
Intervention: Probiotic supplementation (Bifidobacterium breve Bb99 2 × 108 cfu, Propionibacterium freundenreichii subsp. shermanii JS 2 × 109 cfu, Lactobacillus rhamnosus Lc705 5 × 109 cfu, Lactobacillus rhamnosus GG 5 × 109 cfu)
Number of subjects: 199

Group type: COMPARATOR
Intervention: Placebo supplement
Number of subjects: 199
Study: 25730596

Group type: EXPERIMENTAL
Intervention: EX + SUPP (combined home‐based exercise and calcium and vitamin D supplements)
Number of subjects: 43

Group type: COMPARATOR
Intervention: SUPP (calcium and vitamin D supplements alone)
Number of subjects: 43
Study: 25539582

Group type: EXPERIMENTAL
Intervention: DOiT intervention
Number of subjects: 1486
Study: 24006671

Group type: EXPERIMENTAL
Intervention: Manual acupuncture at regional + distal acupoints
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Auricular EA
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Bloodletting at Taiyang (EX‐HN 5) + Ashi points
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Manual acupuncture or EA stimulation
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Auricular acupuncture therapy
Number of subjects: 76

Group type: COMPARATOR
Intervention: No acupuncture stimulation (control for F2)
Number of subjects: 76

Group type: COMPARATOR
Intervention: No acupuncture stimulation (control for F3)
Number of subjects: 76

Group type: COMPARATOR
Intervention: No bloodletting (control for F4)
Number of subjects: 76
Study: 21347978

Group type: EXPERIMENTAL
Intervention: Internet chat groups
Number of subjects: 152

Group type: COMPARATOR
Intervention: Control group (no internet chat groups)
Number of subjects: 152
Study: 18163485

Group type: EXPERIMENTAL
Intervention: Atacicept (70 mg, 210 mg, or 630 mg single doses; 3 doses of 70 mg, 3 doses of 210 mg, or 7 doses of 420 mg repeated doses)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study: 16389028

Group type: EXPERIMENTAL
Intervention: Acute chorioamnionitis
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: Chronic chorioamnionitis
Number of subjects: 227
Study: 14636465

Group type: EXPERIMENTAL
Intervention: Rabeprazole (Rab) 10mg twice daily for two days
Number of subjects: 30

Group type: COMPARATOR
Intervention: Omeprazole (Ome) 20mg twice daily for two days
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Rabeprazole (Rab)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Omeprazole (Ome)
Number of subjects: 30
Study: 10805610

Group type: EXPERIMENTAL
Intervention: Cocaethylene (0.25 or 0.5 mg/kg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cocaine (0.25 or 0.5 mg/kg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cocaethylene
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cocaine
Number of subjects: 0
Study: 8927664

Group type: EXPERIMENTAL
Intervention: Imipramine (IMI)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: N-desmethylimipramine
Number of subjects: 0
Study: 1817902

Group type: EXPERIMENTAL
Intervention: Epinephrine 0.001%
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Norepinephrine 0.005%
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Emotional stress (injection, tooth extraction)
Number of subjects: 0
Study: 6787721

Group type: EXPERIMENTAL
Intervention: Oral gold formulation at 4 mg/d
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Oral gold formulation at 6 mg/d
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 22
Study: 31838256

Group type: EXPERIMENTAL
Intervention: Genetically-guided therapy (Group G)
Number of subjects: 1500

Group type: COMPARATOR
Intervention: Standard therapy (Group S)
Number of subjects: 1500
Study: 30185920

Group type: EXPERIMENTAL
Intervention: Functional Imagery Training (FIT)
Number of subjects: 141

Group type: COMPARATOR
Intervention: Motivational Interviewing (MI)
Number of subjects: 141
Study: 28320866

Group type: EXPERIMENTAL
Intervention: Adenotonsillotomy (ATT)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Adenotonsillectomy (ATE)
Number of subjects: 79
Study: 25933810

Group type: EXPERIMENTAL
Intervention: 3D model of the cardiac lesion(s) during the appointment
Number of subjects: 103

Group type: COMPARATOR
Intervention: Routine visit (Control)
Number of subjects: 103
Study: 24007198

Group type: EXPERIMENTAL
Intervention: Post-Discharge Network Coordination Program
Number of subjects: 160

Group type: COMPARATOR
Intervention: Treatment as usual (Control)
Number of subjects: 160
Study: 21248399

Group type: EXPERIMENTAL
Intervention: Ketoprofen phonophoresis and splinting
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Ultrasound and splinting
Number of subjects: 51

Group type: COMPARATOR
Intervention: Sham ultrasound and splinting
Number of subjects: 51
Study: 18766393

Group type: EXPERIMENTAL
Intervention: Laboratory polysomnography (PSG) studies
Number of subjects: 118
Study: 17310049

Group type: EXPERIMENTAL
Intervention: Educational booklet (primer)
Number of subjects: 555

Group type: COMPARATOR
Intervention: General health booklet (control)
Number of subjects: 555
Study: 15052213

Group type: EXPERIMENTAL
Intervention: Multiple-bypassing (group A)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Single-bypassing (group B)
Number of subjects: 64
Study: 11336163

Group type: EXPERIMENTAL
Intervention: Elemental diet (EO28 Extra)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Polymeric diet (Forticips)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Nutritional supplement (both diets combined)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Nutritional supplement (per-protocol analysis)
Number of subjects: 33
Study: 9239583

Group type: EXPERIMENTAL
Intervention: 25 micrograms/kg fentanyl i.v. (group 1, n = 10)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 3 micrograms/kg sufentanil i.v. (group 2, n = 10)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 6 micrograms/kg sufentanil i.v. (group 3, n = 10)
Number of subjects: 30
Study: 8185029

Group type: EXPERIMENTAL
Intervention: Thrombolysis with urokinase
Number of subjects: 31

Group type: COMPARATOR
Intervention: Surgical thrombectomy
Number of subjects: 31
Study: 3653859

Group type: EXPERIMENTAL
Intervention: Combined modality therapy (radiotherapy and chemotherapy)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 25

Group type: COMPARATOR
Intervention: Radiotherapy alone (stage II disease)
Number of subjects: 25
Study: 29973265

Group type: EXPERIMENTAL
Intervention: Acupuncture treatments for 4 weeks
Number of subjects: 124

Group type: COMPARATOR
Intervention: Methycobal
Number of subjects: 124
Study: 29231606

Group type: EXPERIMENTAL
Intervention: Medicinal-cake-separated moxibustion
Number of subjects: 60

Group type: COMPARATOR
Intervention: Wheat-flour-cake moxibustion
Number of subjects: 60
Study: 25660137

Group type: EXPERIMENTAL
Intervention: Canagliflozin 100 mg
Number of subjects: 2313

Group type: EXPERIMENTAL
Intervention: Canagliflozin 300 mg
Number of subjects: 2313

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2313
Study: 23630244

Group type: EXPERIMENTAL
Intervention: Naturopathic care (enhanced usual care plus individualized care by licensed naturopathic doctors)
Number of subjects: 246

Group type: COMPARATOR
Intervention: Enhanced usual care (control group)
Number of subjects: 246
Study: 22433648

Group type: EXPERIMENTAL
Intervention: Varnish containing CaF(2)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Varnish 'Bifluorid 12®'
Number of subjects: 0
Study: 18215750

Group type: EXPERIMENTAL
Intervention: Dynamic splints
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: No splints
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Static splints
Number of subjects: 15
Study: 16507926

Group type: EXPERIMENTAL
Intervention: Membrane sweeping
Number of subjects: 264

Group type: COMPARATOR
Intervention: No membrane sweeping
Number of subjects: 264
Study: 12835203

Group type: EXPERIMENTAL
Intervention: Food available in à la carte (ALC) areas
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Food available in vending machines (VMs)
Number of subjects: 20

Group type: COMPARATOR
Intervention: School food policies
Number of subjects: 20
Study: 11147619

Group type: EXPERIMENTAL
Intervention: CXR screening
Number of subjects: 37724
Study: 8998024

Group type: EXPERIMENTAL
Intervention: Nurse manager participation in budgeting and staff nurse awareness of costs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Use of information about clinical behavior and cost savings
Number of subjects: 0
Study: 1728831

Group type: EXPERIMENTAL
Intervention: Fluoxetine 60 mg once daily
Number of subjects: 3491

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3491

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 3491
Study: 6376194

Group type: EXPERIMENTAL
Intervention: Surgery alone
Number of subjects: 363

Group type: COMPARATOR
Intervention: Pelvic irradiation or FDV
Number of subjects: 363

Group type: COMPARATOR
Intervention: Whole abdomen + pelvic irradiation or CV or FDV
Number of subjects: 363

Group type: COMPARATOR
Intervention: FDV, T, and CF
Number of subjects: 363
Study: 31254451

Group type: EXPERIMENTAL
Intervention: African Americans with knee OA
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: Adjusted for demographic and psychological health covariates
Number of subjects: 322
Study: 31593273

Group type: EXPERIMENTAL
Intervention: 100 μg of sprifermin administered every 6 months (n=110)
Number of subjects: 549

Group type: EXPERIMENTAL
Intervention: 100 μg of sprifermin administered every 12 months (n=110)
Number of subjects: 549

Group type: EXPERIMENTAL
Intervention: 30 μg of sprifermin administered every 6 months (n=111)
Number of subjects: 549

Group type: EXPERIMENTAL
Intervention: 30 μg of sprifermin administered every 12 months (n=110)
Number of subjects: 549

Group type: COMPARATOR
Intervention: Placebo (n=108)
Number of subjects: 549

Group type: EXPERIMENTAL
Intervention: 100 μg of sprifermin (both dosing schedules)
Number of subjects: 549

Group type: EXPERIMENTAL
Intervention: 30 μg of sprifermin (both dosing schedules)
Number of subjects: 549
Study: 29284503

Group type: EXPERIMENTAL
Intervention: VivaSightTM‐SL tube (VST)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Bronchoscopy
Number of subjects: 46
Study: 26460537

Group type: EXPERIMENTAL
Intervention: Smoking cessation (abstinence for one month)
Number of subjects: 185
Study: 23354532

Group type: EXPERIMENTAL
Intervention: Caffeine (CAF) paired with low energy density yogurt (LED)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo (PLA) paired with low energy density yogurt (LED)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Caffeine (CAF) paired with high energy density yogurt (HED)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo (PLA) paired with high energy density yogurt (HED)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Caffeine (CAF) paired with novel-flavored yogurt
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo (PLA) paired with novel-flavored yogurt
Number of subjects: 62
Study: 21283001

Group type: EXPERIMENTAL
Intervention: Serum procalcitonin levels measured on day 1 and day 3
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Decrease in procalcitonin levels on day 3 from baseline
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Increasing procalcitonin levels
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Radiographic multilobar disease
Number of subjects: 65
Study: 19729375

Group type: COMPARATOR
Intervention: Standard-dose lopinavir/ritonavir
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Low-dose lopinavir/ritonavir
Number of subjects: 24
Study: 16566424

Group type: EXPERIMENTAL
Intervention: Cranberry capsules (twice daily 500 mg)
Number of subjects: 560

Group type: EXPERIMENTAL
Intervention: Oral lactobacilli (twice daily a capsule with > 10^9 colony-forming units of Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14)
Number of subjects: 560

Group type: COMPARATOR
Intervention: Standardised antibiotic therapy (once daily 480 mg trimethoprim-sulfamethoxazole)
Number of subjects: 560

Group type: COMPARATOR
Intervention: Standardised antibiotic therapy
Number of subjects: 560
Study: 12846539

Group type: EXPERIMENTAL
Intervention: 99mTc‐GSA SPECT
Number of subjects: 137
Study: 11044270

Group type: EXPERIMENTAL
Intervention: Combined artesunate-praziquantel
Number of subjects: 110

Group type: COMPARATOR
Intervention: Artesunate alone
Number of subjects: 110

Group type: COMPARATOR
Intervention: Praziquantel alone
Number of subjects: 110
Study: 8973673

Group type: EXPERIMENTAL
Intervention: 10.8-mg goserelin acetate depot every 12 weeks
Number of subjects: 160

Group type: COMPARATOR
Intervention: 3.6-mg goserelin acetate depot every 4 weeks for 12 weeks, then 10.8-mg depot every 12 weeks thereafter
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: 10.8-mg goserelin acetate depot
Number of subjects: 160

Group type: COMPARATOR
Intervention: 3.6-mg goserelin acetate depot
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Both depots
Number of subjects: 160
Study: 1478032

Group type: EXPERIMENTAL
Intervention: Vacuum constriction-band device (Erecaid)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Condom-type device (Synergist)
Number of subjects: 39
Study: 6363220

Group type: EXPERIMENTAL
Intervention: Pirenzepine (100 mg daily: 50 mg before breakfast and before evening meal)
Number of subjects: 254

Group type: COMPARATOR
Intervention: Cimetidine (1000 mg daily: 200 mg with breakfast, lunch, and evening meal, and 400 mg at bedtime)
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 254

Group type: COMPARATOR
Intervention: Cimetidine
Number of subjects: 254
Study: 31091567

Group type: EXPERIMENTAL
Intervention: Multimedia instruction
Number of subjects: 123

Group type: COMPARATOR
Intervention: Conventional method
Number of subjects: 123
Study: 29734180

Group type: EXPERIMENTAL
Intervention: Ranibizumab (PRN regimen)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Ranibizumab (monthly regimen)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Ranibizumab (T&E regimen)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Ranibizumab (overall)
Number of subjects: 64
Study: 26979080

Group type: EXPERIMENTAL
Intervention: Ultrathin strut biodegradable polymer sirolimus-eluting stent (BP-SES)
Number of subjects: 2119

Group type: COMPARATOR
Intervention: Durable-polymer everolimus-eluting stent (DP-EES)
Number of subjects: 2119

Group type: EXPERIMENTAL
Intervention: BP-SES
Number of subjects: 2119

Group type: COMPARATOR
Intervention: DP-EES
Number of subjects: 2119
Study: 25082724

Group type: EXPERIMENTAL
Intervention: Elective repeat cesarean delivery (ERCD)
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Trial of labor (TOL)
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Uncertainty about preferred mode of birth
Number of subjects: 212
Study: 22217510

Group type: EXPERIMENTAL
Intervention: Conventional-dose 17β-estradiol/norethisterone acetate (NETA)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Tibolone
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Low-dose 17β-estradiol/NETA
Number of subjects: 24

Group type: COMPARATOR
Intervention: Raloxifene hydrochloride
Number of subjects: 24
Study: 20171140

Group type: EXPERIMENTAL
Intervention: Doxazosin (DO) 4 mg/day for 2 weeks, then 8 mg/day for 2 weeks
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Doxazosin (DO)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Enalapril (EN) 10 mg/day for 2 weeks, then 20 mg/day for 2 weeks
Number of subjects: 16

Group type: COMPARATOR
Intervention: Enalapril (EN)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Doxazosin (DO) and Enalapril (EN)
Number of subjects: 16
Study: 17364528

Group type: EXPERIMENTAL
Intervention: Inpatient rehabilitation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Increased intensity of rehabilitation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Direct patient involvement in neurorehabilitation goal setting
Number of subjects: 0
Study: 15900358

Group type: EXPERIMENTAL
Intervention: Curettage
Number of subjects: 150

Group type: COMPARATOR
Intervention: Drainage
Number of subjects: 150
Study: 11885848

Group type: EXPERIMENTAL
Intervention: Minidose warfarin (1 mg daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no warfarin)
Number of subjects: 0
Study: 10206930

Group type: EXPERIMENTAL
Intervention: Alcohol and repeated performance (A-R)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Alcohol and double performance (A-D)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo and repeated performance (P-R)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo and double performance (P-D)
Number of subjects: 80
Study: 7572323

Group type: EXPERIMENTAL
Intervention: Calcium supplement (500 mg/day)
Number of subjects: 229

Group type: COMPARATOR
Intervention: Placebo (mean calcium intake = 376 mg/day)
Number of subjects: 229
Study: 2190885

Group type: EXPERIMENTAL
Intervention: High-dose cyclophosphamide (7 g/sqm) + GM-CSF (5.5 micrograms/kg per day for 7-14 days)
Number of subjects: 17

Group type: COMPARATOR
Intervention: High-dose cyclophosphamide (7 g/sqm)
Number of subjects: 17
Study: 7002739

Group type: COMPARATOR
Intervention: Hydrocortisone enemas (Cortenemas)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Hydrocortisone foam (Colifoam)
Number of subjects: 30